What research exists for sapropterin's role in long term cognitive improvement?

What clinical studies track sapropterin’s effect on cognition over years?

Sapropterin is a synthetic form of tetrahydrobiopterin (BH4) that lowers phenylalanine levels in patients with phenylketonuria (PKU) by activating phenylalanine hydroxylase. Studies that follow patients beyond 12 months are scarce. One long-term extension trial followed 99 patients for 3.5 years and reported sustained phenylalanine reductions but did not measure formal cognitive testing at the end of the study [1]. Another extension study that included 20 patients who extended beyond 22 weeks showed persistent phenylalanine control, still lacked cognitive endpoints [2].

When does cognitive testing occur in sapropterin trials?

Most trials use short-term cognitive assessments taken during or right after the 6-week or 22-week periods common to sapropterin studies. Cognitive tests such as the Wechsler Intelligence Scale or the California Verbal Learning Test are rarely applied beyond six months. The few assessments that exist report no significant cognitive gain beyond the time window of acute phenylalanine reduction [3]. The absence of longer-term cognitive data is listed as a gap in several regulatory reviews [4].

Why do researchers claim cognitive improvement is possible?

Researchers point to the correlation between early and continued low phenylalanine levels and better cognitive outcomes in PKU. Low phenylalanine ensures adequate tyrosine availability and dopamine synthesis in the brain. The Theoretic<|eos|>